New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
12:14 EDTMMSI, HSPMerit Medical recalls kits containing previously recalled Hospira product
Merit Medical Systems (MMSI) recalled Custom Procedural Trays/Kits manufactured from April 29, 2013 through August 20, 2013 due to the fact they contained Hospira (HSP) supplied 1% Lidocaine HCl, according to a posting to the FDA's website. The recall notice points out that Hospira previously announced on December 23, 2013 that it had initiated a voluntary nationwide recall to the user level for one lot of Lidocaine HCl Injection due to a reddish orange particulate on the inner surface and floating in the solution. Reference Link
News For MMSI;HSP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 6, 2015
11:43 EDTHSPHospira comments on FDA approval of first biosimilar in the U.S.
Hospira (HSP) said in a statement that it "applauds Sandoz (NVS) and the U.S. FDA on today's FDA approval of the first biosimilar in the United States. This is a watershed moment for improving patient access to safe, effective and more affordable biologic medicines. As a global provider of biosimilars, Hospira has seen first-hand the positive impact of biosimilars in other countries, and we are a proud participant in these early stages of the development of a pathway for these medicines in the United States." "Biosimilars represent a transformational opportunity to improve patient access and provide much-needed financial relief to the U.S. healthcare system," said Sumant Ramachandra, M.D., Ph.D., senior VP, Research & Development and Medical & Regulatory Affairs, and chief scientific officer, Hospira. "This approval is good news for the entire healthcare system and brings us one step closer to making these important medications available for the patients who need them. With two biosimilar applications currently under review by the U.S. FDA, Hospira is committed to bringing more affordable biologic medicines to patients in the United States. We look forward to continuing to partner with the FDA on the approval pathway for our biosimilars, so that more and more patients and healthcare providers have access to the benefits of biosimilars."
March 3, 2015
11:08 EDTMMSIMerit Medical to host investor day
Subscribe for More Information
February 27, 2015
16:15 EDTHSPHospira: No Form 483 observations issued after inspection of Costa Rica facility
Subscribe for More Information
February 26, 2015
09:41 EDTHSPHospira launches generic Remicade, WSJ says
Subscribe for More Information
February 25, 2015
06:00 EDTMMSIMerit Medical price target raised to $21 from $16 at Piper Jaffray
Subscribe for More Information
February 24, 2015
16:16 EDTMMSIMerit Medical sees FY25 EPS 85c-89c, consensus 81c
Subscribe for More Information
16:14 EDTMMSIMerit Medical reports Q4 EPS 26c, consensus 21c
Reports Q4 revenue $132.8M, consensus $132.42M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use